Category: Pα+ - Page 5 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move

Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move

Post published:November 22, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

Post published:November 15, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future of Psychedelic Research and Regulation Under Trump or Harris

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future of Psychedelic Research and Regulation Under Trump or Harris

Post published:November 4, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints

Post published:November 1, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder

Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder

Post published:October 31, 2024
Post category:Analysis News Pα+

Read more about the article Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Post published:October 31, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Post published:October 25, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Post published:October 18, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Post published:October 11, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q3 2024

Psychedelic Funding Update: Q3 2024

Post published:October 8, 2024
Post category:Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.